Newron Pharmaceuticals S.p.A. header image

Newron Pharmaceuticals S.p.A.

NWRN

Equity

ISIN IT0004147952 / Valor 2791431

SIX Swiss Exchange (2026-02-16)
CHF 19.70-1.01%

Newron Pharmaceuticals S.p.A.
UMushroom community rating:

star star star star star
4.50 4 votes No rating yet
NegativeNeutralPositive

About company

Newron Pharmaceuticals S.p.A., established in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, New Jersey, is a biopharmaceutical company specializing in the development of innovative therapies for central and peripheral nervous system disorders. The company aims to expand its product portfolio through both internal research and development and strategic licensing and acquisition of novel compounds targeting the central nervous system (CNS) at various stages of development. Newron's shares are publicly traded on the SIX Swiss Exchange under the ticker symbol NWRN, as well as on the primary market of the Düsseldorf Stock Exchange and XETRA under the trading symbol NP5.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

94.7%1Y
289%3Y
591%5Y

Performance

61.4%1Y
75.4%3Y
73.8%5Y

Volatility

Market cap

510 M

Market cap (USD)

Daily traded volume (Shares)

22,845

Daily traded volume (Shares)

1 day high/low

8.99 / 8.39

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.50

4 votes
Performance:
starstarstarstarstar
3.38
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.50
Nature:
starstarstarstarstar
3.63
Uwe K.
Switzerland, 30 Mar 2025
star star star star star
Könnte interessant sein.
Caterina F
Switzerland, 26 Mar 2025
star star star star star
Worth paying attention to
Markus Fässler
Switzerland, 05 Feb 2024
star star star star star
Evenamide, Newron’s innovative drug to treat schizophrenia, has proven safe and effective in use for TRS patients.

EQUITIES OF THE SAME SECTOR

Novartis Inc
Novartis Inc Novartis Inc Valor: 1200526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.05%CHF 126.46
Savaria Corp
Savaria Corp Savaria Corp Valor: 1385257
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.94%CAD 25.19
Johnson & Johnson
Johnson & Johnson Johnson & Johnson Valor: 943981
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.45%USD 243.45
Novo Nordisk A/S
Novo Nordisk A/S Novo Nordisk A/S Valor: 461641
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.31%USD 49.57
Merck & Co Inc
Merck & Co Inc Merck & Co Inc Valor: 10683053
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.82%USD 121.41
Pfizer Inc
Pfizer Inc Pfizer Inc Valor: 962004
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.40%USD 27.58
Abbott Laboratories
Abbott Laboratories Abbott Laboratories Valor: 903037
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.09%USD 112.68
Essity AB
Essity AB Essity AB Valor: 36846754
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.05%SEK 282.00
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc Zimmer Biomet Holdings Inc Valor: 1262932
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.33%USD 96.45
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd Valor: 758744
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.18%USD 33.98